RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark Therapeutics has a shot at establishing a key role for ...
Cantor Fitzgerald initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $50 price target Aardvark is developing ARD-101, a gut-restricted drug in Phase 3 for Prader ...
4don MSN
The logo'd court at the Big 12 Tournament is causing quite a stir. It's cool or crass, awesome or an eyesore, depending on ...
Crass or cool, awesome or eyesore: Big 12 Tournament’s logo’d court makes a statement either way
featuring black baselines and sidelines and the Big 12 logo splashed across center court. The product is cool or crass, awesome or ugly, depending on who you ask, yet there appeared to be precious ...
The gray-hued floor actually debuted during last week's women's Big 12 Tournament, featuring black baselines and sidelines and the Big 12 logo splashed across center court. The product is cool or ...
Crass or Cool, Awesome or Eyesore: Big 12 Tournament's Logo'd Court Makes a Statement Either Way KANSAS CITY, Mo. (AP) — Big 12 commissioner Brett Yormark wanted the league's postseason ...
Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback